Literature DB >> 19394405

Intracellular targeting and clearance of oligomeric alpha-synuclein alleviates toxicity in mammalian cells.

Bin Yuan1, Michael R Sierks.   

Abstract

Intracellular clearance of toxic protein aggregates represents a promising therapeutic approach to treat protein-misfolding diseases such as Parkinson's and Huntington's diseases. Intracelluarly expressed antibody fragments or intrabodies can be used to bind specific intracellular targets. Addition of a non-traditional secretion signal sequence enables the intrabody to first bind its target inside the cell and then shuttle the bound target through the cell membrane, secreting it from the cell. We intracellularly expressed two different single chain antibody (scFv) fragments targeting either monomeric or oligomeric alpha-synuclein (a-syn), in a mammalian cell model that overexpresses a-syn. Two versions of each intrabody were studied, one with and one without the non-traditional secretion signal. The scFv targeting monomeric a-syn provided little or no reduction in toxicity induced by overexpression of a-syn, however binding and secretion of oligomeric a-syn totally reduced toxicity. Non-traditional intrabody secretion therefore represents an effective method to target and clear a variety of harmful intracellular species.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19394405     DOI: 10.1016/j.neulet.2009.04.046

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

Review 1.  Parkinson's disease dementia and potential therapeutic strategies.

Authors:  John N Caviness; LihFen Lue; Charles H Adler; Douglas G Walker
Journal:  CNS Neurosci Ther       Date:  2010-12-28       Impact factor: 5.243

2.  An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.

Authors:  Christina E Khodr; Mohan K Sapru; Jyothi Pedapati; Ye Han; Neva C West; Adrian P Kells; Krystof S Bankiewicz; Martha C Bohn
Journal:  Brain Res       Date:  2011-04-22       Impact factor: 3.252

Review 3.  Synucleinopathies: common features and hippocampal manifestations.

Authors:  Weiwei Yang; Shun Yu
Journal:  Cell Mol Life Sci       Date:  2016-11-08       Impact factor: 9.261

4.  C-terminal part of α-synuclein mediates its activity in promoting proliferation of dopaminergic cells.

Authors:  Juanjuan Yin; Junyan Han; Chen Zhang; Qiu-Lan Ma; Xin Li; Furong Cheng; Guangwei Liu; Yaohua Li; Kenji Uéda; Piu Chan; Shun Yu
Journal:  J Neural Transm (Vienna)       Date:  2011-02-18       Impact factor: 3.575

5.  Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.

Authors:  Christina E Khodr; Amanda Becerra; Ye Han; Martha C Bohn
Journal:  Brain Res       Date:  2014-01-21       Impact factor: 3.252

6.  Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.

Authors:  Min S Wang; Shanta Boddapati; Sharareh Emadi; Michael R Sierks
Journal:  BMC Neurosci       Date:  2010-04-30       Impact factor: 3.288

7.  The use of phage display to generate conformation-sensor recombinant antibodies.

Authors:  Aftabul Haque; Nicholas K Tonks
Journal:  Nat Protoc       Date:  2012-11-15       Impact factor: 13.491

8.  Single chain variable fragment antibodies block aggregation and toxicity induced by familial ALS-linked mutant forms of SOD1.

Authors:  Ghanashyam D Ghadge; John D Pavlovic; Sujatha P Koduvayur; Brian K Kay; Raymond P Roos
Journal:  Neurobiol Dis       Date:  2013-04-20       Impact factor: 5.996

Review 9.  Intrabodies as neuroprotective therapeutics.

Authors:  Anne Messer; Shubhada N Joshi
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

Review 10.  Gene-based antibody strategies for prion diseases.

Authors:  Alessio Cardinale; Silvia Biocca
Journal:  Int J Cell Biol       Date:  2013-08-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.